ELVN — Enliven Therapeutics Balance Sheet
0.000.00%
- $1.01bn
- $692.34m
- 43
- 24
- 81
- 48
Annual balance sheet for Enliven Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-Q | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 88.2 | 90.3 | 75.5 | 253 | 313 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 90.4 | 92.7 | 77.8 | 266 | 318 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.349 | 0.775 | 1.52 | 1.06 | 0.458 |
Other Long Term Assets | |||||
Total Assets | 90.8 | 93.6 | 83.3 | 272 | 326 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 6.25 | 7.21 | 9.71 | 25.9 | 15.9 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 6.41 | 7.62 | 10.4 | 26 | 15.9 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 84.4 | 86 | 72.9 | 246 | 310 |
Total Liabilities & Shareholders' Equity | 90.8 | 93.6 | 83.3 | 272 | 326 |
Total Common Shares Outstanding |